Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

Datos Bibliográficos

ID23344003
AutoresMarianne J Brady (Rush University), David Cella (0000-0002-9881-4541, Rush University), D F Cella, Fei Mo (0000-0002-2184-4144, Rush University), Amy E Bonomi (0000-0002-7230-0913, Rush University), David S Tulsky (0000-0002-4335-4509, Rush University), Stephen Lloyd (0000-0002-1556-2458, Rush University), S R Lloyd, Shirley Deasy (Rush University), Melody Cobleigh (0000-0001-6385-4693, Rush University), Gail Shiomoto (Rush University)
Año1997
Volumen15
Número3
Páginas974-986
Fecha de publicación1997-03-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaJournal of Clinical Oncology (JOURNAL)
Identificadores de la revistaISSN: 0732-183X • E-ISSN: 1527-7755
EditorialAmerican Society of Clinical Oncology (ASCO) (PUBLISHER)
DOI10.1200/jco.1997.15.3.974
PMID9060536
OpenAlexW1857624176
IdiomaEN
Citas recibidas63
Referencias citadas12

PURPOSE: This is the first published report on the validation of the Functional Assessment of Cancer Therapy-Breast (FACT-B), a 44-item self-report instrument designed to measure multidimensional quality of life (QL) in patients with breast cancer. The FACT-B consists of the FACT-General (FACT-G) plus the Breast Cancer Subscale (BCS), which complements the general scale with items specific to QL in breast cancer. The FACT-B was developed with an emphasis on patients' values and brevity and is available in nine languages. METHODS AND RESULTS: Two validation samples were used for this report. The first (n = 47) was tested twice over a 2-month period to assess sensitivity to change. Significant sensitivity to change in performance status rating (PSR) was demonstrated for the FACT-B total score, the Physical Well-Being (PWB) subscale, the Functional Well-Being (FWB) subscale, and the BCS. Sensitivity to change in QL as measured by the Functional Living Index-Cancer (FLIC) was documented in the FACT-B total score, PWB, FWB, and Emotional Well-Being (EWB). Additional validity and reliability data were obtained from a larger sample (n = 295). The alpha coefficient (internal consistency) for the FACT-B total score was high (alpha = .90), with subscale alpha coefficients ranging from .63 to .86. Evidence supported test-retest reliability, as well as convergent, divergent, and known groups validity. CONCLUSION: The FACT-B is appropriate for use in oncology clinical trials, as well as in clinical practice. It demonstrates ease of administration, brevity, reliability, validity, and sensitivity to change.

Breast cancer · Cancer · Clinical trial · Concurrent validity · Convergent validity · Cronbach's alpha · Internal consistency · Physical therapy · Psychometrics · Quality of life (healthcare) · Rating scale · Reliability (semiconductor) · Scale (ratio) · Statistics · Cancer survivorship and care · Cancer-related cognitive impairment studies · Clinical Psychology · Economic and Financial Impacts of Cancer · Internal Medicine · Mathematics · Medicine · Oncology